Literature DB >> 1969061

Selective 5-lipoxygenase inhibition in ulcerative colitis.

L S Laursen1, J Naesdal, K Bukhave, K Lauritsen, J Rask-Madsen.   

Abstract

Leukotriene B4 (LTB4) and prostaglandin E2 (PGE2) concentrations were measured in rectal dialysis fluid from ten patients with active ulcerative colitis before and after oral administration of 800 mg of the 5-lipoxygenase inhibitor A-64077. The median LTB4 level fell significantly, from 4.9 (range 0.6-20.4) ng/ml before treatment to 1.6 (0.3-5.7) ng/ml after 4 h and 0.7 (0.1-8.0) ng/ml after 8 h; it had returned to pretreatment levels by 28 h. The concentration of PGE2 did not change significantly. The increased generation of 5-lipoxygenase products, such as LTB4, in ulcerative colitis and the potent proinflammatory actions of these products suggest that they have an important role in the amplification of the inflammatory response. A controlled trial to assess the clinical efficacy of A-64077 seems worth while.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969061     DOI: 10.1016/0140-6736(90)90803-d

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  30 in total

Review 1.  The measurement of leukotrienes in human fluids.

Authors:  J Y Westcott
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Evaluation of new therapies for inflammatory bowel disease.

Authors:  E Carty; D S Rampton
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 3.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

4.  Platelet-activating factor synthesis by peritoneal mast cells and its inhibition by two quinoline-based compounds.

Authors:  C M Hogaboam; D Donigi-Gale; T S Shoupe; E Y Bissonnette; A D Befus; J L Wallace
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

5.  The pharmacokinetics of zileuton in healthy young and elderly volunteers.

Authors:  R A Braeckman; G R Granneman; C S Locke; J M Machinist; J H Cavannaugh; W M Awni
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

6.  The effect of food on the pharmacokinetics of zileuton.

Authors:  W M Awni; J H Cavanaugh; G Witt; G R Granneman; L M Dubé
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

7.  Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.

Authors:  W M Awni; Z Hussein; G R Granneman; K J Patterson; L M Dubé; J H Cavanaugh
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

8.  Systemic tumor necrosis factor-alpha production in experimental colitis.

Authors:  D R Mack; A S Lau; P M Sherman
Journal:  Dig Dis Sci       Date:  1992-11       Impact factor: 3.199

9.  Effect of leukotriene C4D4 antagonist on colonic damage induced by intracolonic administration of trinitrobenzene sulfonic acid in rats.

Authors:  M Nishikawa; Y Hikasa; K Hori; N Tanida; T Shimoyama
Journal:  J Gastroenterol       Date:  1995-02       Impact factor: 7.527

10.  In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite.

Authors:  J M Machinist; M J Kukulka; B A Bopp
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.